HQY Quote, Financials, Valuation and Earnings

HealthStream has a net margin of 1.9% compared to HealthEquity's net margin of 7.83%. HealthEquity's return on equity of 4.65% beat HealthStream's return on equity of 5.69%.

HealthEquity has a consensus price target of $113.00, signalling upside risk potential of 13.3%. On the other hand HealthStream has an analysts' consensus of -- which suggests that it could grow by 0.09%. Given that HealthEquity has higher upside potential than HealthStream, analysts believe HealthEquity is more attractive than HealthStream.

HealthEquity has a beta of 0.543, which suggesting that the stock is 45.653% less volatile than S&P 500. In comparison HealthStream has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.425%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HealthStream offers a yield of 0.42% to investors and pays a quarterly dividend of $0.03 per share. HealthEquity pays -- of its earnings as a dividend. HealthStream pays out 20.1% of its earnings as a dividend. HealthStream's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HealthEquity quarterly revenues are $300.4M, which are larger than HealthStream quarterly revenues of $73.1M. HealthEquity's net income of $5.7M is lower than HealthStream's net income of $5.7M. Notably, HealthEquity's price-to-earnings ratio is 91.50x while HealthStream's PE ratio is 49.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 7.66x versus 3.44x for HealthStream. Usually stocks with elevated PS ratios are considered overvalued.

Schrodinger has a net margin of 1.9% compared to HealthEquity's net margin of -108.07%. HealthEquity's return on equity of 4.65% beat Schrodinger's return on equity of -34.83%.

HealthEquity has a consensus price target of $113.00, signalling upside risk potential of 13.3%. On the other hand Schrodinger has an analysts' consensus of $32.00 which suggests that it could grow by 57.4%. Given that Schrodinger has higher upside potential than HealthEquity, analysts believe Schrodinger is more attractive than HealthEquity.

HealthEquity has a beta of 0.543, which suggesting that the stock is 45.653% less volatile than S&P 500. In comparison Schrodinger has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Schrodinger offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity pays -- of its earnings as a dividend. Schrodinger pays out -- of its earnings as a dividend.

HealthEquity quarterly revenues are $300.4M, which are larger than Schrodinger quarterly revenues of $35.3M. HealthEquity's net income of $5.7M is higher than Schrodinger's net income of -$38.1M. Notably, HealthEquity's price-to-earnings ratio is 91.50x while Schrodinger's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 7.66x versus 7.70x for Schrodinger. Usually stocks with elevated PS ratios are considered overvalued.

Simulations Plus has a net margin of 1.9% compared to HealthEquity's net margin of 1.09%. HealthEquity's return on equity of 4.65% beat Simulations Plus's return on equity of 4.58%.

HealthEquity has a consensus price target of $113.00, signalling upside risk potential of 13.3%. On the other hand Simulations Plus has an analysts' consensus of $49.00 which suggests that it could grow by 77.24%. Given that Simulations Plus has higher upside potential than HealthEquity, analysts believe Simulations Plus is more attractive than HealthEquity.

HealthEquity has a beta of 0.543, which suggesting that the stock is 45.653% less volatile than S&P 500. In comparison Simulations Plus has a beta of 0.797, suggesting its less volatile than the S&P 500 by 20.306%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simulations Plus offers a yield of 0.85% to investors and pays a quarterly dividend of $0.06 per share. HealthEquity pays -- of its earnings as a dividend. Simulations Plus pays out 48.18% of its earnings as a dividend. Simulations Plus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HealthEquity quarterly revenues are $300.4M, which are larger than Simulations Plus quarterly revenues of $18.9M. HealthEquity's net income of $5.7M is higher than Simulations Plus's net income of $206K. Notably, HealthEquity's price-to-earnings ratio is 91.50x while Simulations Plus's PE ratio is 70.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 7.66x versus 7.70x for Simulations Plus. Usually stocks with elevated PS ratios are considered overvalued.